IMS 2023 | Promising triplets and agents in R/R myeloma: SVd, Isa-Kd and melflufen
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy, discusses the use of selinexor, bortezomib and dexamethasone (SVd) as a favorable treatment option for patients with relapsed/refractory (R/R) multiple myeloma in the second-line setting. Dr Cerchione also elaborates on the use of isatuximab, carfilzomib and dexamethasone (Isa-Kd) for patients refractory to lenalidomide, and further comments on the role of melflufen in this disease setting. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
